School of Medicine Publications and Presentations
Document Type
Article
Publication Date
2-2025
Abstract
The Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation is one of the most prevailing mutations in various tumors and is difficult to cure. Long-term proliferation in carcinogenesis is primarily initiated by oncogenic KRAS-downstream signaling. Recent research suggests that it also activates the autocrine effect and interplays the tumor microenvironment (TME). Here, we discuss the emerging research, including KRAS mutations to immune evasion in TME, which induce immunological modulation that promotes tumor development. This review gives an overview of the existing knowledge of the underlying connection between KRAS mutations and tumor immune modulation. It also addresses the mechanisms to reduce the effect of oncogenes on the immune system and recent advances in clinical trials for immunotherapy in KRAS-mutated cancers.
Recommended Citation
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025). KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers, 17(5), 785. https://doi.org/10.3390/cancers17050785
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publication Title
Cancers
DOI
10.3390/cancers17050785
Academic Level
faculty
Mentor/PI Department
Immunology and Microbiology
Comments
© 2025 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).